羚锐制药(600285) - 2023 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥806,118,337.89, representing a year-on-year increase of 4.10%[2] - Net profit attributable to shareholders was ¥149,200,935.99, reflecting a year-on-year growth of 10.66%[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥140,617,234.58, with a year-on-year increase of 9.27%[2] - Basic earnings per share for the reporting period was ¥0.268, an increase of 10.29% compared to the same period last year[3] - The company reported a net profit of ¥466,182,042.18 for the year-to-date, which is a 15.01% increase compared to the same period last year[2] - Total operating revenue for the first three quarters of 2023 reached ¥2,506,780,833.45, an increase of 10.06% compared to ¥2,277,024,517.97 in the same period of 2022[37] - In Q3 2023, the company reported a net profit of CNY 466,185,949.16, an increase of 15% compared to CNY 405,415,302.27 in Q3 2022[56] - The company’s total comprehensive income for Q3 2023 was CNY 469,060,652.43, compared to CNY 395,758,779.73 in Q3 2022, reflecting an increase of approximately 18.5%[57] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥4,632,078,172.13, up 6.62% from the end of the previous year[3] - The total assets as of September 30, 2023, were ¥4,632,078,172.13, an increase from ¥4,344,382,669.23 at the end of 2022[35] - The total liabilities increased to CNY 1,913,340,264.82 from CNY 1,785,916,842.12, reflecting a growth of approximately 7.1% year-over-year[54] - The total liabilities as of September 30, 2023, were not explicitly stated but are part of the overall financial assessment[35] Shareholder Information - Shareholders' equity attributable to the parent company was ¥2,711,117,799.71, an increase of 6.28% year-on-year[3] - The company reported a total of 27,730 common shareholders at the end of the reporting period[30] - The largest shareholder, Henan Lingrui Group Co., Ltd., holds 121,817,898 shares, representing 21.48% of total shares[30] Cash Flow - Cash generated from operating activities for the year-to-date was ¥508,689,152.63, reflecting a growth of 6.30%[3] - The company's cash flow from operating activities for the first nine months of 2023 was CNY 2,593,005,785.76, up from CNY 2,417,437,578.46 in the same period of 2022, indicating a growth of about 7.2%[57] - Net cash flow from operating activities was $508,689,152.63, up from $478,524,825.72, representing a growth of around 6.4%[58] - The net cash flow from financing activities in the first three quarters of 2023 was -¥284,020,832.65, compared to -¥324,915,930.88 in the same period of 2022[40] Expenses - Total operating costs for the first three quarters of 2023 were ¥1,988,216,290.95, up from ¥1,908,466,932.13 in 2022, reflecting a year-on-year increase of 4.19%[37] - Research and development expenses for the first three quarters of 2023 amounted to ¥66,451,637.23, slightly down from ¥68,187,400.25 in the previous year[37] - Payments to employees increased to $272,961,449.88 from $241,729,316.33, marking an increase of approximately 12.9%[58] - Tax payments rose to $394,927,587.22 from $316,727,958.78, indicating an increase of about 24.6%[58] Investment Activities - Cash inflows from investment activities were $355,043,568.73, a decrease from $798,736,478.75, showing a decline of approximately 55.6%[58] - Cash outflows from investment activities totaled $541,176,405.91, down from $632,515,671.06, indicating a decrease of about 14.4%[58] - Net cash flow from investment activities was -$186,132,837.18, compared to $166,220,807.69 previously, reflecting a significant shift in cash flow[58] - Cash received from investment activities related to other business was $342,964,333.33, down from $780,000,000.00, reflecting a decrease of approximately 56.1%[58] Future Plans - The company plans to continue expanding its market presence and investing in new product development[2] - The company plans to continue expanding its market presence and investing in new product development, although specific figures were not disclosed in the call[56]